Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis

Recent Patents on CNS Drug Discovery

Volumn 7, Issue 1, 2012, Pages 49-70

  Feledziak, Marion ^a   Lambert, Didier M ^a   Marchand Brynaert, Jacqueline ^a   Muccioli, Giulio G ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

ABHD12; ABHD6; FAAH; Fatty acid amide hydrolase; Inflammation; Inhibitors; MAGL; Monoacylglycerol lipase; Nacylethanolamine hydrolyzing acid amidase; Palmitoylethanolamide

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 7 PHENYL 1 [5 (2 PYRIDINYL) 2 OXAZOLYL] 1 HEPTANONE; ACYLGLYCEROL LIPASE; ANANDAMIDE; CANNABINOID RECEPTOR; CAY 10499; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; HYDROLASE; JNJ 1661010; JZL 184; JZL 195; OMDM 169; PALMIDROL; PF 04457845; PF 3845; PF 622; PF 750; PHOSPHOLIPASE INHIBITOR; SAR 629; ST 3899; ST 4020; ST 4070; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 602; URB 694; URB 783; URB 894; URB 937; US 2006293310; US 2009163508; US 2011028478; US 2011028482; US 2011034437; WO 2006044617; WO 2006054652; WO 2006074025; WO 2006088075; WO 2006117461; WO 2007005510; WO 2007020888; WO 2007022501; WO 2007061862; WO 2007098142; WO 2007140005; WO 2008020866; WO 2008021625; WO 2008023720; WO 2008030532; WO 2008047229; WO 2008063300; WO 2008063714; WO 2008129129; WO 2008145839; WO 2008145842; WO 2008145843; WO 2008147553; WO 2008150492; WO 2008153752; WO 2008157740; WO 2009011904; WO 2009049238; WO 2009052319; WO 2009084970; WO 2009105220; WO 2009109743; WO 2009117444; WO 2009126691; WO 2009127943; WO 2009127944; WO 2009127948; WO 2009127949; WO 2009151991; WO 2009152025; WO 2010005572; WO 2010010288; WO 2010017079; WO 2010039186; WO 2010049841; WO 2010055267; WO 2010056309; WO 2010058318; WO 2010059610; WO 2010068453; WO 2010074587; WO 2010089510; WO 2010101724; WO 2010118155; WO 2010118159; WO 2010124114; WO 2010124121; WO 2010124122; WO 2010130943; WO 2010130944; WO 2010130945; WO 2010135360; WO 2010141809; WO 2010151160; WO 2011022348; WO 2011060026; WO 2011071996;

ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL;

AMIDOHYDROLASES; ANIMALS; CENTRAL NERVOUS SYSTEM; ENDOCANNABINOIDS; ENZYME INHIBITORS; HUMANS; HYDROLYSIS; MONOACYLGLYCEROL LIPASES;

EID: 84857408437     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488912798842223     Document Type: Article

References (214)

1. Muccioli GG. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 2010; 15(11-12): 474-83.
2. CravattBF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384(6604): 83-7.
3. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci 2002; 99(16): 10819-24.
4. Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 2004; 66(5): 1260-4.
5. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 2006; 281(48): 36569-78.
6. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007; 14: 1347-56.
7. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 2010; 13(8): 951-7.
8. Ueda N, Tsuboi K, Lambert DM. A second N-acylethanolamine hydrolase in mammalian tissues. Neuropharmacol 2005; 48(8): 1079-85.
9. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci 2009; 106(48): 20270-5.
10. Patricelli MP, Cravatt BF. Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism. Biochem1999; 38(43): 14125-30.
11. Patricelli MP, Lovato MA, Cravatt BF. Chemical and mutagenic investigations of fatty acid amide hydrolase:α Evidence for a Family of Serine Hydrolases with Distinct Catalytic Properties†. Biochemistry 1999; 38(31): 9804-9812.
12. Giang DK, Cravatt BF, Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl. Acad. Sci. U.S.A. 1997; 94(6): 2238-2242.
13. Fowler CJ, Jonsson K-O, Tiger G. Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. Biochem Pharmacol 2001; 62(5): 517-26.
14. Bisogno T, De Petrocellis L, Di Marzo V. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des 2002; 8: 533-47.
15. Saghatelian A, McKinney MK, Bandell M, Patapoutian A, Cravatt BF. A FAAH-regulated class of N-Acyl Taurines that activates TRP ion channels. Biochem 2006; 45(30): 9007-15.
16. Patricelli MP, Patterson JE, Boger DL, Cravatt BF. An endogenous sleep-inducing compound is a novel competitive inhibitor of fatty acid amide hydrolase. Bioorg Med Chem Lett 1998; 8(6): 613-8.
17. Fowler CJ. Oleamide: a member of the endocannabinoid family? Br. J Pharmacol 2004; 141(2): 195-6.
18. Hu SS-J, Bradshaw HB, Benton VM, Chen JS-C, Huang SM, Minassi A, et al. The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. Prostaglandins Leukot Essent Fatty Acids 2009; 81(4): 291-301.
19. Bradshaw H, Rimmerman N, Hu S, Benton V, Stuart J, Masuda K, et al. The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. Biochem 2009; 10(1): 14.
20. Kinsey SG, Long JZ, Cravatt BF, Lichtman AH. Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce antiallodynic effects in mice through distinct cannabinoid receptor mechanisms. J Pain 2010; 11(12): 1420-8.
21. Alexander SPH, Kendall DA. The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 2007; 152(5): 602-23.
22. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58(3): 389-462.
23. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994; 270(1): 219-27.
24. Godlewski G, Alapafuja SO, Bátkai S, Nikas SP, Cinar R, Offertáler L, et al. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem Biol 2010; 17(11): 1256-66.
25. Bashashati M, Storr MA, Nikas SP, Wood JT, Godlewski G, Liu J, et al. Inhibiting fatty acid amide normalizes endotoxin-induced enhanced gastrointestinal motility in the mouse. Br J Pharmacol 2011: accepted article.
26. Hansen HS, Diep TA. N-acylethanolamines, anandamide and food intake. Biochem Pharmacol 2009; 78(6): 553-60.
27. Calignano A, Rana GL, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394(6690): 277-81.
28. Jaggar SI, Hasnie FS, Sellaturay S, Rice ASC. The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76(1-2): 189-99.
29. Parolaro D, Realini N, Vigano D, Guidali C, Rubino T. The endocannabinoid system and psychiatric disorders. Exp Neurol 2010; 224(1): 3-14.
30. Bisogno T, Sepe N, De Petrocellis L, Mechoulam R, Di Marzo V. The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun 1997; 239(2): 473-9.
31. Boger DL, Henriksen SJ, Cravatt BF. Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Curr Pharm Des 1998; 4: 303-14.
32. Lambert DM, Vandevoorde S, Jonsson K-O, Fowler CJ. The palmitoylethanolamide family: A new class of anti-inflammatory agents? Curr Med Chem 2002; 9: 663-74.
33. Thabuis C, Tissot-Favre D, Bezelgues J-B, Martin J-C, Cruz-Hernandez C, Dionisi F, et al. Biological Functions and Metabolism of Oleoylethanolamide. Lipids 2008; 43(10): 887-94.
34. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez de Fonseca F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-[alpha]. Nature 2003; 425(6953): 90-3.
35. Schlosburg J, Carlson B, Ramesh D, Abdullah R, Long J, Cravatt B, et al. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 2009; 11(2): 342-52.
36. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, et al. Blockade of endocannabinoid-degrading enzymes Attenuates neuropathic pain. J Pharmacol Exp Ther 2009; 330(3): 902-10.
37. Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007; 152(5): 624-32.
38. Ezzili C, Mileni M, McGlinchey N, Long JZ, Kinsey SG, Hochstatter DG, et al. Reversible competitive α-ketoheterocycle inhibitors of fatty acid amide hydrolase containing additional conformational constraints in the acyl side chain: Orally active, long-acting analgesics. J Med Chem 2011; 54(8): 2805-22.
39. Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, et al. Mechanistic and pharmacological characterization of PF-04457845: A highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther 2011; 338(1): 114-24.
40. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH. Inhibition of endocannabinoid catabolic enzymes elicits anxiolyticlike effects in the marble burying assay. Pharmacol Biochem Behav 2011; 98(1): 21-7.
41. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 2009; 30(9): 484-93.
42. Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D, et al. International review of neurobiology. G. Bagetta, M.T. Corasaniti, T. Sakurada, and S. Sakurada 2009: 57-72.
43. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Sci 2002; 298(5599): 1793-6.
44. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005; 74: 411-32.
45. Michaux C, Labar G. Fatty acid amide hydrolase: from characterisation to therapeutics. Chem Biodivers 2007; 4: 1882-902.
46. Mileni M, Johnson DS, Wang Z, Everdeen DS, Liimatta M, Pabst B, et al. Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci U.S.A. 2008; 105(35): 12820-4.
47. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory Pain Chem Biol 2009; 16(4): 411-20.
48. Mileni M, Garfunkle J, DeMartino JK, Cravatt BF, Boger DL, Stevens RC. Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by α-Ketoheterocycle Inhibitors Revealed from Cocrystal Structures. J. Am. Chem. Soc. 2009; 131(30): 10497-10506.
49. Mileni M, Garfunkle J, Ezzili C, Kimball FS, Cravatt BF, Stevens RC, et al. X-ray crystallographic analysis of α-Ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. J Med Chem 2010; 53(1): 230-40.
50. Mileni M, Kamtekar S, Wood DC, Benson TE, Cravatt BF, Stevens RC. Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. J Mol Biol 2010; 400(4): 743-54.
51. Feledziak M, Michaux C, Urbach A, Labar G, Muccioli GG, Lambert DM, et al. β-Lactams derived from a carbapenem chiron are selective inhibitors of human fatty acid amide hydrolase versus human monoacylglycerol lipase. J Med Chem 2009; 52(22): 7054-68.
52. Seierstad M, Breitenbucher JG. Discovery and development of fatty acid amide hydrolase (FAAH) Inhibitors J Med Chem 2008; 51(23): 7327-43.
53. Vandevoorde S. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr Top Med Chem 2008; 8: 247-67.
54. Minkkila A, Saario SM, Nevalainen T. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors. Curr Top Med Chem 2010; 10(8): 828-58.
55. Deng HF. Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors. Expert Opin Drug Dis 2010; 5(10): 961-93.
56. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci U.S.A. 2000; 97(10): 5044-9.
57. Tarzia G, Duranti A, Tontini A, Piersanti G, Mor M, Rivara S, et al. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem 2003; 46(12): 2352-60.
58. Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 2007; 46(45): 13019-13030.
59. Edwards PD, Meyer EF, Vijayalakshmi J, Tuthill PA, Andisik DA, Gomes B, et al. Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl. alpha.-ketobenzoxazoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole. J Am Chem Soc 1992; 114(5): 1854-63.
60. Edwards PD, Wolanin DJ, Andisik DW, Davis MW. Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 2. Effect of varying the heterocyclic ring on in vitro potency. J Med Chem 1995; 38(1): 76-85.
61. Boger, D.L. Oxadiazole ketones as inhibitors of fatty acid amide hydrolase, their preparation, pharmaceutical compositions, and use in therapy. WO2006044617 (2006).
62. Boger, D.L. Preparation of phenylheteroaryloxadiazolylheptanone derivatives and analogs for use as FAAH inhibitors. WO2010005572 (2010).
63. Boger, D. Preparation of keto-oxazole compounds as modulators of fatty acid amide hydrolase. WO2007098142 (2007).
64. Boger, D.L. Preparation of oxazole derivatives as fatty acid amide hydrolase inhibitors. WO2008030532 (2008).
65. Boger, D.L. Tetracyclic compounds as inhibitors of fatty acid amide hydrolase and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008147553 (2008).
66. Boger, D.L. Preparation of oxazole derivatives as inhibitors of fatty acid amide hydrolase (FAAH). WO2008150492 (2008).
67. Apocada, R., Breintenbucher, J.G., Epperson, M.T., Fried, A.K., Pippel, D. J., Seierstad, M. 2-keto-oxazoles as modulators of fatty acid amide hydrolase WO2007061862 (2007).
68. Apodaca, R., Breitenbucher, J. G., Chambers, A. L., Seierstad, M., Xiao, W. Preparation of oxazolyl piperidinyl methanones as modulators of fatty acid amide hydrolase. WO2007140005 (2007).
69. Alexander JP, Cravatt BF. Mechanism of carbamate inactivation of FAAH: Implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol 2005; 12(11): 1179-87.
70. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, et al. Cyclohexylcarbamic Acid 3'-or 4'-Substituted Biphenyl-3-yl Esters as fatty acid amide hydrolase inhibitors:α synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 2004; 47(21): 4998-5008.
71. Piomelli, D., Duranti, A., Tontini, A., Mor, M., Tarzia, G. Preparation and use of carbamates for modulation of anxiety through blockade of anandamide hydrolysis. WO2004033422 (2004).
72. Dasse, O., Putman, D., Compton, T. R., Parrott, J. A. Metabolically stabilized inhibitors of fatty acid amide hydrolase, and use in the treatment of pain. WO2008063714 (2008).
73. Dasse, O., Putman, D., Compton, T., R Ionizable inhibitors of fatty acid amide hydrolase WO2008020866 (2008).
74. Dasse, O. Combination FAAH inhibitor and analgesic, antiinflammatory or anti-pyretic agent. WO2008021625 (2008).
75. Dasse, O., Putman, D., Compton, T. R., Parrott, J. Alkylcarbamic acid ester inhibitors of fatty acid amide hydrolase, and therapeutic use. WO2007079180 (2007).
76. Putman, D., Parrott, J., Compton, T.R., Dasse, O. Alkylcarbamic acid esters as inhibitors of fatty acid amide hydrolase. WO2008024139 (2008).
77. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 2004; 311(2): 441-8.
78. Zhang D. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacol 2007; 52: 1095-105.
79. Tarzia G, Duranti A, Gatti G, Piersanti G, Tontini A, Rivara S, et al. Synthesis and structure-activity relationships of FAAH Inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. Chem Med Chem 2006; 1(1): 130-9.
80. Clapper JR, Vacondio F, King AR, Duranti A, Tontini A, Silva C, et al. A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. Chem Med Chem 2009; 4(9): 1505-13.
81. Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 2010; 13(10): 1265-70.
82. Ishii, T., Sugane, T., Maeda, J., Narazaki, F., Kakefuda, A., Sato, K., Takahashi, T., Kanayama, T., Saitoh, C., Suzuki, J., Kanai, C. Preparation of pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivatives as FAAH inhibitors. WO2006088075 (2006).
83. Myllymaeki, M., Castillo-Melendez, J., Koskinen, A., Minkkilae, A., Saario, S., Nevalainen, T., Jaervinen, T., Poso, A., Salo-Ahen, O. Preparation of heterocyclic phenyl carbamates as novel FAAH inhibitors. WO2008129129 (2008).
84. Almario-Garcia, A., George, P., Hoornaert, C., Li, A.-T., Puech, F. Alkyl, alkenyl and alkynyl carbamate derivatives, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies. WO2006117461 (2006).
85. Abouabdellah, A., Chereze, N., Fayol, A., Saady, M., Vache, J., Veronique, C., Yaiche, P. Carbamate derivatives of alkyl heterocycles, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies. WO2010055267 (2010).
86. Abouabdellah, A., Goerlitzer, J., Hamley, P., Ravet, A. Alkylthiazolyl carbamates, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies. WO2010010288 (2010).
87. Abouabdellah, A., Fayol, A., Lochead, A., Saady, M., Vache, J., Yaiche, P. Cyclopenta[c]pyrrolylalkylcarbamate derivatives of 5-membered heterocycles, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies. WO2010130943 (2010).
88. Abouabdellah, A., Even, L., Fayol, A., Vache, J., Yaiche, P. (5-Membered heterocyclyl)alkyl cyclopenta[c]pyrrolylalkylcarboxylate derivatives, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies. WO2010130944 (2010).
89. Abouabdellah, A., Chereze, N., Fayol, A., Lochead, A., Saady, M., Vache, J., Yaiche, P. (5-Membered heterocyclyl)alkyl 7-azaspiro[3,5]nonane-7-carboxylate derivatives, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies. WO2010130945 (2010).
90. Abouabdellah, A., Chereze, N., Fayol, A., Lochead, A., Saady, M., Vache, J., Yaiche, P. Azaspiranyl-alkylcarbamate derivatives of 5-membered heterocycles, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies. WO2010089510 (2010).
91. Abouabdellah, A., Almario Garcia, A., Hoornaert, C., Li, A. T Derivatives of 1-piperazine-and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme US2006293310 (2006).
92. Minetti, P., Cabri, W., Dallavalle, S., Merlini, L., Penco, S., Borsini, F., Caprioli, A., Maccarrone, M. Enol carbamate derivatives as inhibitors of fatty acid amide hydrolase useful in the treatment of diseases and preparation and pharmaceutical compositions thereof. WO2009109504 (2009).
93. Minetti, P., Cabri, W., Borsini, F., Caprioli, A., Penco, S., Dallavalle, S., Merlini, L., Maccarrone, M. Oxime carbamoyl derivatives as modulators of fatty acid amide hydrolase. WO2009138416 (2009).
94. Apodaca, R., Breitenbucher, J.G., Pattabiraman, K., Seierstad, M., Xiao, W. Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase. WO2006074025 (2006).
95. Matsumoto, T., Kori, M., Miyazaki, J., Kiyota, Y. Preparation of piperidinecarboxamides and piperazinecarboxamides as fatty acid amide hydrolase (FAAH) inhibitors. WO2006054652 (2006).
96. Fay, L.K., Johnson, D.S., Lazerwith, S.E., Morris, M.A., Wang, L.J., Meyers, M.J., Kesten, S.R., Stiff, C.M. Preparation of (hetero)biaryl ether methylidenepiperidinyl ureas as fatty acid amide hydrolase (FAAH) inhibitors. WO2008047229 (2008).
97. Fay, L.K., Johnson, D.S., Meyers, M.J., Schweitzer, B.A., Thorarensen, A., Wang, L.J. Ether benzylidene piperidine 5-membered aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127943 (2009).
98. Fay, L.K., Johnson, D.S., Meyers, M.J., Thorarensen, A., Wang, L.J. Ether benzylidene piperidine aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127944 (2009).
99. Meyers, M.J., Pelc, M.J., Thorarensen, A., Schweitzer, B. A. 4-[3-(Aryloxy)benzylidene]-3-methylpiperidine 5-membered aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127948 (2009).
100. Meyers, M.J., Pelc, M.J., Thorarensen, A. 4-[3-(Aryloxy)benzylidene]-3-methylpiperidine aryl carboxamide compounds useful as FAAH inhibitors and their preparation. WO2009127949 (2009).
101. Long, S.A., Meyers, M.J., Pelc, M.J., Schweitzer, B.A., Thorarensen, A., Wang, L.J. Preparation of 7-azaspiro[3.5]nonane-7-carboxamides as inhibitors of fatty acid amide hydrolase (FAAH). WO2010049841 (2010).
102. Long, S.A., Meyers, M.J., Pelc, M.J., Schweitzer, B.A., Thorarensen, A., Wang, L.J. Preparation of 1-Oxa-8-azaspiro[4,5]decane-8-carboxamide compounds as FAAH inhibitors for therapy. WO2010058318 (2010).
103. Even, L., Hoornaert, C. Derivatives of triazolopyridine carboxamides, particularly (piperazin-1-yl)(1,2,3-triazolo[4,5-b]pyridin-1-yl)methanones, their preparation and use as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors. WO2008145843 (2008).
104. Even, L., Hoornaert, C. Derivatives of triazolopyridine carboxamides, particularly (piperazin-1-yl)(1,2,3-triazolo[4,5-b]pyridin-1-yl)methanones and (piperidin-1-yl)(1,2,3-triazolo[4,5-b]pyridin-1-yl) methanones, their preparation and use as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors. WO2008145839 (2008).
105. Apodaca, R., Breitenbucher, J.G., Pattabiraman, K., Seierstad, M., Xiao, W. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase. WO2007005510 (2007).
106. Apodaca, R., Breitenbucher, J. G., Hawryluk, N., A, Jones, W., M, Keith, J., M, Merit, J., E, Tichenor, M., S, Timmons, A., K Heteroaryl-substituted urea modulators of fatty acid amide hydrolase. WO2008153752 (2008)
107. Breitenbucher, J. G., Keith, J. M., Tichenor, M. S., Chambers, A. L., Jones, W. M., Hawryluk, N. A., Timmons, A. K., Merit, J. E., Seierstad, M. J. Preparation of heteroaryl-substituted urea modulators of fatty acid amide hydrolase. WO2010068453 (2010)
108. Hawryluk, N.A. Preparation of piperazinecarboxamide derivative as fatty acid amide hydrolase modulator. WO2011060026 (2011).
109. Ishii, T., Sugane, T., Kakefuda, A., Takahashi, T., Kanayama, T., Sato, K., Kuriwaki, I., Kitada, C., Suzuki, J. Preparation of piperazine-1-carboxamide and piperidine-1-carboxamide derivatives as inhibitors of fatty acid amide hydrolase (FAAH). WO2008023720 (2008).
110. Kori, M.M.K. amide compounds. US2009163508 (2009).
111. Matsumoto, T., Kori, M., Kouno, M. Preparation of piperazine-1-carboxamide derivatives as brain/neuronal cell-protecting agents, and therapeutic agents for sleep disorder. WO2007020888 (2007).
112. Roughley, S., Walls, S., Hart, T., Parsons, R., Brough, P., Graham, C., Macias, A. Azetidine derivatives as inhibitors of fatty acid amide hydrolase useful in the treatment of diseases and preparation and pharmaceutical compositions thereof. WO2009109743 (2009).
113. Breitenbucher, G.J., Tichenor, M.S., Merit, J.E., Hawryluk, N.A., Chambers, A. L., Keith, J.M. Preparation of aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase. WO2010141809 (2010).
114. Breitenbucher, G.J., Keith, J. M., Jones, W.M. Preparation of heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase inhibitors. WO2010141817 (2010).
115. Yang, W., Gao, X., Wang, B. Boronic acid compounds as potential pharmaceutical agents. Med Res Rev 2003; 23(3): 346-68.
116. Adams, J., Behnke, M.L., Castro, A.C., Evans, C.A., Grenier, L., Grogan, M.J., Liu, T., Snyder, D.A., Tibbitts, T.T. Preparation of arylboronates as inhibitors of fatty acid amide hydrolase. WO2008063300 (2008).
117. Minkkila A, Saario SM, Kasnanen H, Leppanen J, Poso A, Nevalainen T. Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem 2008; 51(22): 7057-60.
118. Behnke, M.L., Castro, A.C., Evans, C.A., Grenier, L., Grogan, M.J., Liu, T., Snyder, D.A., Tibbitts, T.T. Preparation of oxadiazolylphenylboronic acid derivatives and analogs for use as fatty acid amide hydrolase inhibitors. WO2009126691 (2009).
119. Castro, A.C., Grogan, M.J., Snyder, D.A. Inhibitors of fatty acid amide hydrolase. WO2010118155 (2010).
120. Castro, A. C., Evans, C. A., Grenier, L., Grogan, M. J. Preparation of piperidineboronic acid derivatives for use as fatty acid amide hydrolase inhibitors. WO2010118159 (2010)
121. Bartolini, W., Cali, B.M., Chen, B., Chen, Y.-T., Currie, M.G., Milne, G.T., Pearson, J.P., Talley, J.J., Yang, J.J., Zimmerman, C. Preparation of indoleacetates as modulators of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2), cyclooxygenase-2 (COX-2) and fatty acid amide hydrolase (FAAH). WO2006036994 (2006).
122. Sprott, K., Talley, J.J., Pearson, J.P., Milne, T.G. Indole derivatives as FAAH inhibitors and their preparation and use in the treatment of diseases. WO2008157740 (2008).
123. Bartolini, W., Cali, B.M., Chen, B., Chien, Y.-T., Currie, M.G., Milne, G.T., Pearson, J.P., Talley, J.J., Yang, J.J., Zimmerman, C., Monreal, A.W. Preparation of indolylalkanoates as modulators of CRTH2, COX-1, COX-2, CD11B, TXA2, DAO, DP1, and/or FAAH. WO2007022501 (2007).
124. Bartolini, W., Cali, B.M., Chen, B., Chien, Y.-T., Currie, M.G., Milne, G.T., Pearson, J.P., Talley, J.J., Zimmerman, C. Synthesis of COX-2 and FAAH inhibitors. WO2006050120 (2006).
125. Sprott, K., Talley, J.J., Yang, J., Peng, B. Preparation of benzylpyrrolyloxoacetamide derivatives for use as FAAH inhibitors. WO2011071996 (2011).
126. Learmonth, D.A., Kiss, L.E., Beliaev, A., Ferreira, H.D.S., Silva, P.M.V.A.S.D. 5-O-Substituted 3-N-phenyl-1,3,4-oxadiazolones as FAAH inhibitors and their preparation and use in the treatment of diseases. WO2009084970 (2009).
127. Learmonth, D.A., Da Silva, P.M.V.A.S. 5-O-Substituted 3-N-aryl-1,3,4-oxadiazolone derivatives as FAAH inhibitors and their preparation and use for the treatment of diseases. WO2010074587 (2010).
128. Learmonth, D.A., Da Silva, P.M.V.A.S., Kiss, L.E. Preparation of N-heteroaryloxadiazolone derivatives for use as FAAH inhibitors. WO2010151160 (2010).
129. Lin, L.S., Chioda, M. D., Liu, P., Nargund, R.P. Preparation of imidazole derivatives useful as inhibitors of FAAH. WO2009152025 (2009).
130. Liu, P., Devita, R.J., Lin, L.S., Chioda, M.D., Hamill, T.G., Li, W. Imidazole derivatives useful as modulators of FAAH and as FAAH imaging agents WO2010101724 (2010).
131. Lin, L.S., Chang, L.L., Chobanian, H., Nargund, R.P. Pyrazole derivatives useful as inhibitors of FAAH. WO2009151991 (2009).
132. Chobanian, H., Lin, L. S., Liu, P., Chioda, M. D., Devita, R. J., Nargund, R. P., Guo, Y. Preparation of oxazole derivatives as inhibitors of FAAH. WO2010017079 (2010).
133. Kelly, M.G., Kincaid, J., Gowlugari, S., Kaub, C. Preparation of substituted naphthyridines as FAAH modulators. WO2009011904 (2009).
134. Kaub, C., Gowlugari, S., Kincaid, J., Johnson, R.J., O'Mahony, D.J.R., Estiarte-Martinez, M.d.L.A., Duncton, M. Preparation of benzoxazole compounds as FAAH modulators. WO2010039186 (2010).
135. Duncton, M., O'Mahony, D.J.R., Cox, M. 6,7-Dihydro-5Hpyrrolo[3,4-d]pyrimidin-4-yl(quinolin-3-yl)amine derivatives as FAAH modulators and their preparation and use for the treatment of diseases. WO2010059610 (2010).
136. Apodaca, R., Breitenbucher, J.G., Chambers, A.L., Deng, X., Hawryluk, N.A., Keith, J.M., Mani, N.S., Merit, J.E., Pierce, J.M., Seierstad, M., Xiao, W. Preparation of aryl-hydroxyethylaminopyrimidines and triazines as modulators of fatty acid amide hydrolase. WO2009105220 (2009).
137. Hawryluk, N.A., Breitenbucher, J.G., Jones, W.M., Chambers, A.L., Keith, J. M., Seierstad, M. Preparation of pyrimidinyl ethylene diamine derivatives as modulators of fatty acid amide hydrolase. WO2011022348 (2011).
138. Behnke, M.L., Castro, A.C., Chan, L.K., Evans, C.A., Grenier, L., Grogan, M.J., Leblanc, Y., Liu, T., Peluso, S., Snyder, D.A., Tibbitts, T.T. Preparation of isoxazoline derivatives for use as fatty acid amide hydrolase inhibitors. WO2010135360 (2010).
139. Behnke, M.L., Castro, A.C., Chan, L.K., Evans, C.A., Grenier, L., Grogan, M.J., Leblanc, Y., Liu, T., Peluso, S., Snyder, D.A., Tibbitts, T.T. Isoxazolines as inhibitors of fatty acid amide hydrolase US2011028478 (2011).
140. Behnke, M.L., Castro, A.C., Chan, L.K., Evans, C.A., Grenier, L., Grogan, M.J., Leblanc, Y., Liu, T., Peluso, S., Snyder, D.A., Tibbitts, T.T. Isoxazolines as inhibitors of fatty acid amide hydrolase. US2011034437 (2011).
141. Muccioli GG, Fazio N, Scriba GKE, Poppitz W, Cannata F, Poupaert JH, et al. Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates. J Med Chem 2006; 49(1): 417-25.
142. Wang X, Sarris K, Kage K, Zhang D, Brown SP, Kolasa T, et al. Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J Med Chem 2008; 52(1): 170-80.
143. Onnis V, Congiu C, Bjorklund E, Hempel F, Soderstrom E, Fowler CJ. Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors. J Med Chem 2010; 53(5): 2286-98.
144. De Wael F, Muccioli GG, Lambert DM, Sergent T, Schneider Y-J, Rees J-F, et al. Chemistry around imidazopyrazine and ibuprofen: Discovery of novel fatty acid amide hydrolase (FAAH) inhibitors. Eur J Med Chem 2010; 45(9): 3564-74.
145. Forster L, Ludwig J, Kaptur M, Bovens S, Elfringhoff AS, Holtfrerich A, et al. 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A2[alpha] and fatty acid amide hydrolase. Bioorg Med Chem 2010; 18(2): 945-52.
146. Feledziak M, Muccioli GG, Lambert DM, Marchand-Brynaert J. SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): Evidence of a Nonhydrolytic Process. J Med Chem 2011; 54(19): 6812-23.
147. Min X, Thibault ST, Porter AC, Gustin DJ, Carlson TJ, Xu H, et al. Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH). Proc. Natl. Acad. Sci. 2011; 108(18): 7379-84.
148. Tornqvist H, Belfrage P. Purification and some properties of a monoacylglycerol-hydrolyzing enzyme of rat adipose tissue. J Biol Chem 1976; 251(3): 813-9.
149. Kupiecki FP. Partial purification of monoglyceride lipase from adipose tissue. J Lipid Res 1966; 7(2): 230-5.
150. Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. J Biol Chem 1997; 272(43): 27218-23.
151. Saario SM. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem Biol 2005; 12: 649-56.
152. Zvonok N, Pandarinathan L, Williams J, Johnston M, Karageorgos I, Janero DR, et al. Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chem Biol 2008; 15(8): 854-62.
153. King AR, Lodola A, Carmi C, Fu J, Mor M, Piomelli D. A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. Br J Pharmacol 2009; 157(6): 974-83.
154. Kapanda CN, Muccioli GG, Labar G, Poupaert JH, Lambert DM. Bis(dialkylaminethiocarbonyl)disulfides as Potent and Selective Monoglyceride Lipase Inhibitors. J Med Chem 2009; 52(22): 7310-4.
155. Labar G, Bauvois C, Borel F, Ferrer J-L, Wouters J, Lambert DM. Crystal structure of the human monoacylglycerol lipase, a key actor in endocannabinoid signaling. Chem Bio Chem 2010; 11(2): 218-227.
156. Bertrand T, Augé F, Houtmann J, Rak A, Vallée F, Mikol V, et al. Structural basis for human monoglyceride lipase inhibition. J Mol Biol 2010; 396(3): 663-73.
157. Sugiura T, Kishimoto S, Oka S, Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006; 45(5): 405-46.
158. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413(6855): 527-531.
159. Panikashvili D, Shein NAA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 2006; 22(2): 257-64.
160. Zhang J, Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem 2008; 283(33): 22601-11.
161. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136(4): 550-7.
162. Tuboly G, Mecs L, Benedek G, Horvath G. Antinociceptive interactions between anandamide and endomorphin-1 at the spinal level. Clin Exp Pharmacol Physiol 2009; 36: 400-5.
163. Guindon J, Hohmann AG, The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 2011; 163(7): 1447-63.
164. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng S-W, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010; 140(1): 49-61.
165. Bisogno T, Ortar G, Petrosino S, Morera E, Palazzo E, Nalli M, et al. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim Biophys Acta 2009; 1791(1): 53-60.
166. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B. The inhibition of monoacylglycerol lipase by URB602 showed an antiinflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol 2007; 152(5): 787-94.
167. Kinsey SG, Nomura DK, O'Neal ST, Long JZ, Mahadevan A, Cravatt BF, et al. Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 2011;338(3):795-802
168. Alhouayek M, Lambert DM, Delzenne NM, Cani PD, Muccioli GG. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 2011.
169. Sticht MA, Long JZ, Rock EM, Limebeer CL, Mechoulam R, Cravatt BF, et al. The MAGL inhibitor, JZL184, attenuates LiClinduced vomiting in the Suncus murinus and 2AG attenuates LiClinduced nausea-like behavior in rats. Br J Pharmacol 2011: no-no.
170. Labar G, Wouters J, Lambert DM. A review on the monoacylglycerol lipase: at the interface between fat and endocannabinoid signalling. Curr Med Chem 2010; 17(24): 2588-607.
171. Hoornaert C. Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof. WO2008145842 (2008).
172. Makriyannis, A., Pandarinathan, L., Zvonok, N., Parkkari, T., Chapman, L. Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors. WO2009117444 (2009).
173. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. An endocannabinoid mechanism for stressinduced analgesia. Nature 2005; 435: 1108-12.
174. Vandevoorde S, Jonsson KO, Labar G, Persson E, Lambert DM, Fowler CJ. Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 2007; 150: 186-91.
175. Saario SM, Palomäki V, Lehtonen M, Nevalainen T, Järvinen T, Laitinen JT. URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain. Chem Biol 2006; 13(8): 811-4.
176. Long JZ, Jin X, Adibekian A, Li W, Cravatt BF. Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases. J Med Chem 2010; 53(4): 1830-42.
177. Cravatt, B.F., Long, J.Z., Li, W., Nomura, D.K. Methods and compositions related to targeting monoacylglycerol lipase. WO2010056309 (2010).
178. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009; 5(1): 37-44.
179. Makriyannis, A., Nikas, S.P., Alapafuja, S.O., Shukla, V.G. Sulfonyl fluorides, trifluoromethyl ketones, carbamates, α-ketooxadiazoles and saccharin analogues as monoacylglycerol lipase inhibitors for modulation of cannabinoid activity and their preparations, pharmaceutical compositions and use in the treatment of diseases. WO2009052319 (2009)
180. Bian, H., Chevalier, K.M., Connolly, P.J., Flores, C.M., Lin, S.-C., Liu, L., Mabus, J., Macielag, M.J., Mcdonnell, M.E., Pitis, P.M., Zhang, Y.-M., Zhang, S.-P., Clemente, J., Zhu, B. Azetidinyl diamides as monoacylglycerol lipase inhibitors. WO2010124114 (2010).
181. Chevalier, K.M., Dax, S.L., Flores, C.M., Liu, L., Macielag, M.J., Mcdonnell, M.E., Nelen, M.I., Prouty, S., Todd, M., Zhang, S.-P., Zhu, B., Nulton, E.L., Clemente, J. Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors WO2010124121 (2010).
182. Flores, C.M., Nelen, M.I., Nulton, E.L., Prouty, S., Todd, M., Zhang, S.-P. Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors WO2010124122 (2010).
183. Schubert, C., Grasberger, B.L., Schalk-Hihi, C., Maguire, D.M., Lewandowski, F.A., Milligan, C.M., Alexander, R.S. Crystal structure and alternative crystal form of human monoacylglycerol lipase (MGLL), and use for design and screening of MGLL inhibitors. WO2009132267 (2010).
184. Schalk-Hihi C, Schubert C, Alexander R, Bayoumy S, Clemente JC, Deckman I, et al. Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 Å resolution. Protein Sci 2011; 20(4): 670-83.
185. Muccioli GG, Labar G, Lambert DM. CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay. ChemBioChem 2008; 9(16): 2704-10.
186. Minkkilä A, Savinainen JR, Käsnänen H, Xhaard H, Nevalainen T, Laitinen JT, et al. Screening of various hormone-sensitive lipase inhibitors as endocannabinoid-hydrolyzing enzyme inhibitors. Chem Med Chem 2009; 4(8): 1253-9.
187. Tsuboi K, Takezaki N, Ueda N. The N-acylethanolaminehydrolyzing acid amidase (NAAA). Chem Biodivers 2007; 4(8): 1914-25.
188. Ueda N, Yamanaka K, Yamamoto S. Purification and characterization of an acid amidase selective for Npalmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 2001; 276(38): 35552-7.
189. Tsuboi K, Sun Y-X, Okamoto Y, Araki N, Tonai T, Ueda N. Molecular characterization of N-Acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 2005; 280(12): 11082-92.
190. Tsuboi K, Zhao L-Y, Okamoto Y, Araki N, Ueno M, Sakamoto H, et al. Predominant expression of lysosomal N-acylethanolaminehydrolyzing acid amidase in macrophages revealed by immunochemical studies. Biochim Biophys Acta 2007; 1771(5): 623-32.
191. Tsuboi K, Takezaki N, Ueda N. The N-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA). Chemistry & Biodiversity 2007; 4(8): 1914-25.
192. Oinonen C, Rouvinen J. Structural comparison of Ntn-hydrolases. Protein Sci 2000; 9(12): 2329-37.
193. Wang J, Zhao L-Y, Uyama T, Tsuboi K, Tonai T, Ueda N. Amino acid residues crucial in pH regulation and proteolytic activation of N-acylethanolamine-hydrolyzing acid amidase. Biochim Biophys Acta 2008; 1781(11-12): 710-7.
194. Fegley, D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3[prime]-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005; 313: 352-8.
195. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A, N-(2-Hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 1996; 300(3): 227-36.
196. Lambert DM, Vandevoorde S, Diependaele G, Govaerts SJ, Robert AR. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 2001; 42(3): 321-7.
197. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67(1): 15-9.
198. Vandevoorde S, Jonsson KO, Fowler CJ, Lambert DM. Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide. J Med Chem 2003; 46(8): 1440-8.
199. Vandevoorde S, Tsuboi K, Ueda N, Jonsson K-O, Fowler CJ, Lambert DM. Esters, retroesters, and a retroamide of palmitic acid: pool for the first selective inhibitors of n-palmitoylethanolamineselective acid amidase. J Med Chem 2003; 46(21): 4373-6.
200. Tsuboi K, Hilligsmann C, Vandevoorde S, Lambert DM, Ueda N. N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem J 2004; 379(1): 99-106.
201. Saturnino C, Petrosino S, Ligresti A, Palladino C, Martino GD, Bisogno T, et al. Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. Bioorg Med Chem Lett 2010; 20(3): 1210-3.
202. Piomelli, D., Tarzia, G., Mor, M., Duranti, A., Tontini, A. Preparation of oxooxetanes and related compounds as NAAA (Nacylethanolamine-hydrolyzing acid amidase) inhibitors. WO2009049238 (2009).
203. Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, et al. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci 2009; 106(49): 20966-71.
204. Solorzano C, Antonietti F, Duranti A, Tontini A, Rivara S, Lodola A, et al. Synthesis and structure-activity relationships of N-(2-Oxo-3-oxetanyl) amides as N-Acylethanolamine-hydrolyzing Acid Amidase Inhibitors. J Med Chem 2010; 53(15): 5770-81.
205. Long JZ, Nomura DK, Cravatt BF. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 2009; 16(7): 744-53.
206. Long JZ, LaCava M, Jin X, Cravatt BF. An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase. J Lipid Res 2011; 52(2): 337-44.
207. Chanda PK, Gao Y, Mark L, Btesh J, Strassle BW, Lu P, et al. A., Monoacylglycerol Lipase Activity Is a Critical Modulator of the Tone and Integrity of the Endocannabinoid System. Mol Pharmacol 2010; 78(6): 996-1003.
208. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 2010; 13(9): 1113-19.
209. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Sci 2011; In Press (DOI 10.1126/science.1209200).
210. Li W, Blankman JL, Cravatt BF. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J Am Chem Soc 2007; 129: 9594-5.
211. Bachovchin DA, Ji T, Li W, Simon GM, Blankman JL, Adibekian A, et al. Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. Proc Natl Acad Sci 2010; 107(49): 20941-6.
212. Marrs WR, Horne EA, Ortega-Gutierrez S, Cisneros JA, Xu C, Lin YH, et al. Dual inhibition of α/β-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons. J Biol Chem 2011; 286(33): 28723-8.
213. Xie S, Borazjani A, Hatfield MJ, Edwards CC, Potter PM, Ross MK. Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2. Chem Res Toxicol 2010; 23(12): 1890-904.
214. Sun Y-X, Tsuboi K, Zhao L-Y, Okamoto Y, Lambert DM, Ueda N. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta 2005; 1736(3): 211-20.